Thelansis

 Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by profound elevations in low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. HoFH significantly raises the risk of premature coronary artery disease. This condition is associated with a deficiency or absence of LDL-C receptors, which can be attributed to mutations affecting the binding site of apolipoprotein B-100 (apoB-100) on LDL-C receptors and mutations in PCSK9 and LDLRAP1. The LDLR gene is situated on chromosome 19's short arm. LDL-C receptors play a vital role in the liver's uptake of approximately 70% of circulating LDL-C molecules. A decrease in LDL-C receptors results in accelerated cholesterol deposition within arterial walls. This, in turn, leads to arterial hardening, narrowing, and reduced blood flow, predisposing individuals to cardiovascular diseases such as stroke and myocardial infarction. ·        In the United States, as of...

 Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder that causes severe elevations in low-density lipoproteins cholesterol (LDL-C) and total cholesterol. Those with HoFH have a very high chance of premature coronary artery disease. Familial hypercholesterolemia is a deficiency or absence of the LDL-C receptors. It can also be caused by mutations of the apolipoprotein B-100 (apoB-100) binding site on LDL-C receptors, PCSK9, and LDLRAP1. The LDLR gene is located on the short arm of chromosome 19.6 LDL-C receptors are responsible for about 70% of the uptake of circulating LDL-C molecules into the liver. Reductions in the number of LDL-C receptors lead to an accelerated deposition of cholesterol on the walls of arteries. The arteries then harden and narrow and reduce the flow of blood. This reduction in blood flow can lead to cardiovascular diseases like stroke and myocardial infarction. ·        In 2020, the estimated prevalence of HoF...